12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

Afraxis, Genentech, Roche deal

Roche's Genentech unit acquired from Afraxis its therapeutic business, which comprises a portfolio of compounds against undisclosed, novel targets that Afraxis said covers a range of neurology, inflammation and cancer indications. Afraxis is eligible to receive up to $187.5 million in an undisclosed...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >